Target intelligence / Profile preview

Trans-activation response element RNA (TAR RNA)

Target
TAR RNA
Molecular classification
Other (RNA regulatory element), Viral RNA structural element, Pre-microRNA
01

Overview

The Trans-activation response element RNA (TAR RNA) is a stem-loop structure present at the 5′ ends of HIV-1 transcripts. It is central for HIV-1 transcriptional activation; binding of the viral Tat protein to TAR recruits host transcriptional machinery (notably P-TEFb, a complex of Cyclin T1 and CDK9), resulting in enhanced elongation of viral RNA by RNA polymerase II[4][2][3][5][9]. TAR RNA functions in multiple stages of the HIV life cycle: reverse transcription, transcription, genome dimerization, packaging, and modulation of innate immune responses via inhibition of PKR[2]. It also acts as a precursor to viral microRNAs that protect infected cells from apoptosis[4]. Inhibiting the Tat-TAR interaction is a major focus in HIV drug development, but no clinical drugs specifically target TAR directly[2][4]. TAR is dynamic, with both the upper stem (major Tat-binding site) and lower stem (PKR interaction) required for optimal viral replication[2]. Its function is structurally dependent: loss or mutation of critical bulges/loops impairs Tat binding and viral transcription[1][6][5]. The TAR element also serves as an enhancer for transcriptional processivity and acts as a switch for viral gene expression[7].

Other names
HIV-1 TARTAR elementTransactivation response element
02

Mechanism of action

Tat inhibitors prevent Tat-TAR binding, disrupting HIV transcriptional elongation. PKR activators could overcome TAR's suppression of innate immunity.

03

Biological functions

Transcriptional activationViral genome replicationImmune response modulationApoptosis regulationRNA packaging/dimerization
04

Disease associations

InfectionOther (potentially relevant in JC virus due to homologous elements)
05

Safety considerations

Therapeutic challenge: RNA-targeted drugs must avoid off-target effects on host RNAs.Viral escape: High viral mutation rates may reduce efficacy of TAR-specific interventions.
06

Interacting drugs

None approved for direct TAR binding

3 more in the full profile.

07

Biomarkers

Presence/structure of TAR in viral genomesTAR-derived miRNAs detectable in infected cells

Beyond the preview

Go deeper on Trans-activation response element RNA (TAR RNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans-activation response element RNA (TAR RNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call